
|Videos|September 29, 2022
Dr. Joyce on financial toxicity and advanced prostate cancer treatments
Author(s)Urology Times staff
“We really need to be thoughtful about how our treatment recommendations may induce financial toxicity in patients with advanced prostate cancer,” says Daniel D. Joyce, MD.
Advertisement
In this video, Daniel D. Joyce, MD, discusses the take-home message from the recent Journal of Urology study, “Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients,” for which he served as a study author. Joyce is a urologic oncology fellow at Mayo Clinic, Rochester, Minnesota.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
4
Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care
5










